Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 132.4% in January

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 92,500 shares, a growth of 132.4% from the January 15th total of 39,800 shares. Based on an average daily volume of 497,000 shares, the short-interest ratio is presently 0.2 days.

Astellas Pharma Price Performance

OTCMKTS ALPMY traded up $0.04 during trading hours on Monday, reaching $9.77. The company's stock had a trading volume of 94,114 shares, compared to its average volume of 241,071. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.86 and a current ratio of 1.10. The company's 50-day moving average is $9.68 and its two-hundred day moving average is $10.88. Astellas Pharma has a fifty-two week low of $9.05 and a fifty-two week high of $13.14. The stock has a market cap of $17.68 billion, a PE ratio of -44.41 and a beta of 0.34.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.48%. Analysts forecast that Astellas Pharma will post 0.58 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.